The DOI matches its Crossref record; 74 of the 74 references it cites were found in a registry or an index.
Intratumor depletion of CD4+ cells unmasks tumor immunogenicity leading to the rejection of late-stage tumors
Open accessAbstract
Tumor environment can be critical for preventing the immunological destruction of antigenic tumors. We have observed a selective accumulation of CD4+CD25+ T cells inside tumors. In a murine fibrosarcoma Ld-expressing Ag104, these cells made up the majority of tumor-infiltrating lymphocytes at the late stage of tumor progression, and their depletion during the effector phase, rather than priming phase, successfully enhanced antitumor immunity. We show here that CD4+CD25+ T cells suppressed the proliferation and interferon-γ production of CD8+ T cells in vivo at the local tumor site. Blockade of the effects of IL-10 and TGF-β partially reversed the suppression imposed by the CD4+ cells. Furthermore, local depletion of CD4+ cells inside the tumor resulted in a change of cytokine milieu and led to the eradication of well-established highly aggressive tumors and the development of long-term antitumor memory. Therefore, CD4+CD25+ T cells maintained an environment in the tumor that concealed the immunogenicity of tumor cells to permit progressive growth of antigenic tumors. Our study illustrates that the suppression of antitumor immunity by regulatory T cells occurs predominantly at the tumor site, and that local reversal of suppression, even at a late stage of tumor development, can be an effective treatment for well-established cancers.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Control of Regulatory T Cell Development by the Transcription Factor Foxp3
Hori, S., Nomura, T., & Sakaguchi, S. (2003) · Science · doi:10.1126/science.1079490 · Cited by 8,187
Foxp3 programs the development and function of CD4+CD25+ regulatory T cells
Fontenot, J. D., Gavin, M. A., & Rudensky, A. Y. (2003) · Nature Immunology · doi:10.1038/ni904 · Cited by 7,745
Curiel, T. J., Coukos, G., Zou, L., Alvarez, X., Cheng, P., Mottram, P., Evdemon-Hogan, M., Conejo-Garcia, J. R., Zhang, L., Burow, M., et al. (2004) · Nature Medicine · doi:10.1038/nm1093 · Cited by 5,151
The Role of Tumoral FOXP3 on Cell Proliferation, Migration, and Invasion in Gastric Cancer
Zhang, L., Xu, J., Zhang, X., Zhang, Y., Wang, L., Huang, X., & Xu, Z. (2017) · Cellular Physiology and Biochemistry · doi:10.1159/000479442 · Cited by 4,088
Intratumoral T Cells, Recurrence, and Survival in Epithelial Ovarian Cancer
Zhang, L., Conejo-Garcia, J. R., Katsaros, D., Gimotty, P. A., Massobrio, M., Regnani, G., Makrigiannakis, A., Gray, H., Schlienger, K., Liebman, M. N., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa020177 · Cited by 3,397
Sakaguchi, S. (2004) · Annual Review of Immunology · doi:10.1146/annurev.immunol.21.120601.141122 · Cited by 3,306
The Three Es of Cancer Immunoediting
Dunn, G. P., Old, L. J., & Schreiber, R. D. (2004) · Annual Review of Immunology · doi:10.1146/annurev.immunol.22.012703.104803 · Cited by 3,072
An essential role for Scurfin in CD4+CD25+ T regulatory cells
Khattri, R., Cox, T., Yasayko, S.-A., & Ramsdell, F. (2003) · Nature Immunology · doi:10.1038/ni909 · Cited by 2,856
Cancer Regression and Autoimmunity in Patients After Clonal Repopulation with Antitumor Lymphocytes
Dudley, M. E., Wunderlich, J. R., Robbins, P. F., Yang, J. C., Hwu, P., Schwartzentruber, D. J., Topalian, S. L., Sherry, R., Restifo, N. P., Hubicki, A. M., et al. (2002) · Science · doi:10.1126/science.1076514 · Cited by 2,823
CD4+CD25+ suppressor T cells: more questions than answers
Shevach, E. M. (2002) · Nature Reviews Immunology · doi:10.1038/nri821 · Cited by 2,110
CD4+CD25+ regulatory T cells control Leishmania major persistence and immunity
Belkaid, Y., Piccirillo, C. A., Mendez, S., Shevach, E. M., & Sacks, D. L. (2002) · Nature · doi:10.1038/nature01152 · Cited by 1,725
CD4+ T cells are required for secondary expansion and memory in CD8+ T lymphocytes
Janssen, E. M., Lemmens, E. E., Wolfe, T., Christen, U., von Herrath, M. G., & Schoenberger, S. P. (2003) · Nature · doi:10.1038/nature01441 · Cited by 1,635
Positive and negative selection of T cells
Starr, T. K., Jameson, S. C., & Hogquist, K. A. (2003) · Annual Review of Immunology · doi:10.1146/annurev.immunol.21.120601.141107 · Cited by 1,601
Shimizu, J., Yamazaki, S., & Sakaguchi, S. (1999) · The Journal of Immunology · doi:10.4049/jimmunol.163.10.5211 · Cited by 1,491
Liyanage, U. K., Moore, T. T., Joo, H.-G., Tanaka, Y., Herrmann, V., Doherty, G., Drebin, J. A., Strasberg, S. M., Eberlein, T. J., Goedegebuure, P. S., et al. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.169.5.2756 · Cited by 1,467
Requirement for CD4 T Cell Help in Generating Functional CD8 T Cell Memory
Shedlock, D. J., & Shen, H. (2003) · Science · doi:10.1126/science.1082305 · Cited by 1,460
Model Predicting Survival in Stage I Melanoma Based on Tumor Progression
Clark, W. H., Elder, D. E., Guerry, D., Braitman, L. E., Trock, B. J., Schultz, D., Synnestvedt, M., & Halpern, A. C. (1989) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/81.24.1893 · Cited by 1,247
Defective CD8 T Cell Memory Following Acute Infection Without CD4 T Cell Help
Sun, J. C., & Bevan, M. J. (2003) · Science · doi:10.1126/science.1083317 · Cited by 1,213
Regulatory T cells in the control of immune pathology
Maloy, K. J., & Powrie, F. (2001) · Nature Immunology · doi:10.1038/ni0901-816 · Cited by 1,175
Clemente, C. G., Mihm, M. C., Bufalino, R., Zurrida, S., Collini, P., & Cascinelli, N. (1996) · Cancer · doi:10.1002/(sici)1097-0142(19960401)77:7<1303::aid-cncr12>3.0.co;2-5 · Cited by 1,171
A p16 INK4a -Insensitive CDK4 Mutant Targeted by Cytolytic T Lymphocytes in a Human Melanoma
Wölfel, T., Hauer, M., Schneider, J., Serrano, M., Wölfel, C., Klehmann-Hieb, E., De Plaen, E., Hankeln, T., Meyer zum Büschenfelde, K.-H., & Beach, D. (1995) · Science · doi:10.1126/science.7652577 · Cited by 1,154
Dieckmann, D., Plottner, H., Berchtold, S., Berger, T., & Schuler, G. (2001) · The Journal of Experimental Medicine · doi:10.1084/jem.193.11.1303 · Cited by 1,139
Woo, E. Y., Chu, C., Goletz, T. J., Schlienger, K., Yeh, H., Coukos, G., Rubin, S. C., Kaiser, L. R., & June, C. H. (2001) · PubMed · Cited by 1,108
Onizuka, S., Tawara, I., Shimizu, J., Sakaguchi, S., Fujita, T., & Nakayama, E. (1999) · PubMed · Cited by 1,062
Sutmuller, R. P. M., van Duivenvoorde, L. M., van Elsas, A., Schumacher, T. N. M., Wildenberg, M. E., Allison, J. P., Toes, R. E. M., Offringa, R., & Melief, C. J. M. (2001) · The Journal of Experimental Medicine · doi:10.1084/jem.194.6.823 · Cited by 1,008
Monoclonal antibodies against the 4-1BB T-cell activation molecule eradicate established tumors
Melero, I., Shuford, W. W., Newby, S. A., Aruffo, A., Ledbetter, J. A., Hellström, K. E., Mittler, R. S., & Chen, L. (1997) · Nature Medicine · doi:10.1038/nm0697-682 · Cited by 898
Human tumor antigens recognized by T lymphocytes.
Boon, T., & van der Bruggen, P. (1996) · The Journal of experimental medicine · doi:10.1084/jem.183.3.725 · Cited by 842
Does the Immune System See Tumors as Foreign or Self?
Pardoll, D. (2003) · Annual Review of Immunology · doi:10.1146/annurev.immunol.21.120601.141135 · Cited by 753
Sakaguchi, S., Fukuma, K., Kuribayashi, K., & Masuda, T. (1985) · The Journal of experimental medicine · doi:10.1084/jem.161.1.72 · Cited by 729
Woo, E. Y., Yeh, H., Chu, C. S., Schlienger, K., Carroll, R. G., Riley, J. L., Kaiser, L. R., & June, C. H. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.168.9.4272 · Cited by 696
A New Era for Cancer Immunotherapy Based on the Genes that Encode Cancer Antigens
Rosenberg, S. A. (1999) · Immunity · doi:10.1016/s1074-7613(00)80028-x · Cited by 566
Robbins, P. F., El-Gamil, M., Li, Y. F., Kawakami, Y., Loftus, D., Appella, E., & Rosenberg, S. A. (1996) · The Journal of experimental medicine · doi:10.1084/jem.183.3.1185 · Cited by 550
Concomitant Tumor Immunity to a Poorly Immunogenic Melanoma Is Prevented by Regulatory T Cells
Turk, M. J., Guevara-Patiño, J. A., Rizzuto, G. A., Engelhorn, M. E., & Houghton, A. N. (2004) · The Journal of Experimental Medicine · doi:10.1084/jem.20041130 · Cited by 540
Tumor-Specific Human CD4+ Regulatory T Cells and Their Ligands
Wang, H. Y., Lee, D. A., Peng, G., Guo, Z., Li, Y., Kiniwa, Y., Shevach, E. M., & Wang, R.-F. (2004) · Immunity · doi:10.1016/s1074-7613(03)00359-5 · Cited by 515
CD4 T Cells and Their Role in Antitumor Immune Responses
Toes, R. E. M., Ossendorp, F., Offringa, R., & Melief, C. J. M. (1999) · The Journal of Experimental Medicine · doi:10.1084/jem.189.5.753 · Cited by 508
Negative selection — clearing out the bad apples from the T-cell repertoire
Palmer, E. (2003) · Nature Reviews Immunology · doi:10.1038/nri1085 · Cited by 504
Machiels, J.-P., Reilly, R. T., Emens, L. A., Ercolini, A. M., Lei, R. Y., Weintraub, D., Okoye, F. I., & Jaffee, E. M. (2001) · PubMed · Cited by 453
Coulie, P. G., Lehmann, F., Lethé, B., Herman, J., Lurquin, C., Andrawiss, M., & Boon, T. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.17.7976 · Cited by 423
Cancer antigens: immune recognition of self and altered self.
Houghton, A. N. (1994) · The Journal of experimental medicine · doi:10.1084/jem.180.1.1 · Cited by 420
Regulatory T cells under scrutiny
François Bach, J. (2003) · Nature Reviews Immunology · doi:10.1038/nri1026 · Cited by 413
The Makings of a Tumor Rejection Antigen
Gilboa, E. (1999) · Immunity · doi:10.1016/s1074-7613(00)80101-6 · Cited by 381
Berendt, M. J., & North, R. J. (1980) · The Journal of experimental medicine · doi:10.1084/jem.151.1.69 · Cited by 369
Priming of naive T cells inside tumors leads to eradication of established tumors
Yu, P., Lee, Y., Liu, W., Chin, R. K., Wang, J., Wang, Y., Schietinger, A., Philip, M., Schreiber, H., & Fu, Y.-X. (2004) · Nature Immunology · doi:10.1038/ni1029 · Cited by 356
Self-citationNakagomi, H., Petersson, M., Magnusson, I., Juhlin, C., Matsuda, M., Mellstedt, H., Taupin, J., Vivier, É., Anderson, P., & Kiessling, R. W. (1993) · PubMed · Cited by 339
A CASP-8 Mutation Recognized by Cytolytic T Lymphocytes on a Human Head and Neck Carcinoma
Mandruzzato, S., Brasseur, F., Andry, G., Boon, T., & Bruggen, P. V. D. (1997) · The Journal of Experimental Medicine · doi:10.1084/jem.186.5.785 · Cited by 321
van Elsas, A., Sutmuller, R. P. M., Hurwitz, A. A., Ziskin, J., Villasenor, J., Medema, J.-P., Overwijk, W. W., Restifo, N. P., Melief, C. J. M., Offringa, R., et al. (2001) · The Journal of Experimental Medicine · doi:10.1084/jem.194.4.481 · Cited by 309
De Plaen, E., Lurquin, C., Van Pel, A., Mariamé, B., Szikora, J. P., Wölfel, T., Sibille, C., Chomez, P., & Boon, T. (1988) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.85.7.2274 · Cited by 308
Lurquin, C., Van Pel, A., Mariamé, B., De Plaen, E., Szikora, J.-P., Janssens, C., Reddehase, M. J., Lejeune, J., & Boon, T. (1989) · Cell · doi:10.1016/0092-8674(89)90844-1 · Cited by 300
Van den Eynde, B., Lethé, B., Van Pel, A., De Plaen, E., & Boon, T. (1991) · The Journal of experimental medicine · doi:10.1084/jem.173.6.1373 · Cited by 298
Golgher, D., Jones, E., Powrie, F., Elliott, T., & Gallimore, A. (2002) · European Journal of Immunology · doi:10.1002/1521-4141(200211)32:11<3267::aid-immu3267>3.0.co;2-1 · Cited by 282
The role of MHC class II-restricted tumor antigens and CD4+ T cells in antitumor immunity
Wang, R.-F. (2001) · Trends in Immunology · doi:10.1016/s1471-4906(01)01896-8 · Cited by 266
Uyttenhove, C., Maryanski, J., & Boon, T. (1983) · The Journal of experimental medicine · doi:10.1084/jem.157.3.1040 · Cited by 245
A unique tumor antigen produced by a single amino acid substitution
Monach, P. A., Meredith, S. C., T.Siegel, C., & Schreiber, H. (1995) · Immunity · doi:10.1016/1074-7613(95)90078-0 · Cited by 241
Self-citationSpiotto, M. T., Yu, P., Rowley, D. A., Nishimura, M. I., Meredith, S. C., Gajewski, T. F., Fu, Y.-X., & Schreiber, H. (2002) · Immunity · doi:10.1016/s1074-7613(02)00480-6 · Cited by 236
Self-citationSteitz, J., Brück, J., Lenz, J., Knop, J., & Tüting, T. (2001) · PubMed · Cited by 214
Jones, E., Dahm‐Vicker, M., Simon, A. K., Green, A., Powrie, F. M., Cerundolo, V., & Gallimore, A. (2002) · PubMed · Cited by 208
Casares, N., Arribillaga, L., Sarobe, P., Dotor, J., Lopez-Diaz de Cerio, A., Melero, I., Prieto, J., Borrás-Cuesta, F., & Lasarte, J. J. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.171.11.5931 · Cited by 196
Wick, M., Dubey, P., Koeppen, H., Siegel, C. T., Fields, P. E., Chen, L., Bluestone, J. A., & Schreiber, H. (1997) · The Journal of Experimental Medicine · doi:10.1084/jem.186.2.229 · Cited by 195
Self-citationImmunity against cancer: lessons learned from melanoma
Houghton, A. N., Gold, J. S., & Blachere, N. E. (2001) · Current Opinion in Immunology · doi:10.1016/s0952-7915(00)00195-3 · Cited by 190
Stroma is critical for preventing or permitting immunological destruction of antigenic cancer cells.
Singh, S., Ross, S. R., Acena, M., Rowley, D. A., & Schreiber, H. (1992) · The Journal of experimental medicine · doi:10.1084/jem.175.1.139 · Cited by 170
Self-citationSignaling via LTβR on the lamina propria stromal cells of the gut is required for IgA production
Kang, H.-S., Chin, R., Wang, Y., Yu, P., Wang, J., Newell, K. A., & Fu, Y. (2002) · Nature Immunology · doi:10.1038/ni795 · Cited by 149
Self-citationConcomitant Tumor Immunity and the Resistance to a Second Tumor Challenge
Gorelik, E. (1983) · Advances in cancer research · doi:10.1016/s0065-230x(08)61033-7 · Cited by 135
Awwad, M., & North, R. J. (1988) · The Journal of Experimental Medicine · doi:10.1084/jem.168.6.2193 · Cited by 111
Importance of CD4+ T helper cell responses in tumor immunity
OSSENDORP, F. A., Toes, R. E. M., Offringa, R., van der Burg, S. H., & Melief, C. J. M. (2000) · Immunology Letters · doi:10.1016/s0165-2478(00)00252-2 · Cited by 92
Bursuker, I., & North, R. J. (1984) · The Journal of Experimental Medicine · doi:10.1084/jem.159.5.1312 · Cited by 88
Yu, P., Spiotto, M. T., Lee, Y., Schreiber, H. W., & Fu, Y. (2003) · The Journal of Experimental Medicine · doi:10.1084/jem.20021804 · Cited by 75
Self-citationSugihara, S., Izumi, Y., Yoshioka, T., Yagi, H., Tsujimura, T., Tarutani, O., Kohno, Y., Murakami, S., Hamaoka, T., & Fujiwara, H. (1988) · The Journal of Immunology · doi:10.4049/jimmunol.141.1.105 · Cited by 72
Li, J., Hu, P., Khawli, L. A., & Epstein, A. L. (2003) · PubMed · Cited by 66
Immunoselection of tumor cell variants by mice suppressed with ultraviolet radiation.
Urban, J. L., Holland, J. M., Kripke, M. L., et al. (1982) · The Journal of Experimental Medicine · doi:10.1084/jem.156.4.1025 · Cited by 49
Point Mutation in Essential Genes with Loss or Mutation of the Second Allele
Beck‐Engeser, G., Monach, P. A., Mumberg, D., Yang, F. E., Wanderling, S. S., Schreiber, K., Espinosa, R., Beau, M. M. L., Meredith, S. C., & Schreiber, H. W. (2001) · The Journal of Experimental Medicine · doi:10.1084/jem.194.3.285 · Cited by 46
Self-citationIdentification of a Mutated Fibronectin As a Tumor Antigen Recognized by CD4+T Cells
Wang, H. Y., Zhou, J., Zhu, K., Riker, A. I., Marincola, F. M., & Wang, R. (2002) · The Journal of Experimental Medicine · doi:10.1084/jem.20020141 · Cited by 40
Perdrizet, G. A., Ross, S. R., Stauss, H. J., Singh, S. P., Koeppen, H., & Schreiber, H. W. (1990) · The Journal of Experimental Medicine · doi:10.1084/jem.171.4.1205 · Cited by 30
Self-citationTawara, I., Take, Y., Uenaka, A., Noguchi, Y., & Nakayama, E. (2002) · Japanese Journal of Cancer Research · doi:10.1111/j.1349-7006.2002.tb01337.x · Cited by 26
Cited by
Polarization of Tumor-Associated Neutrophil Phenotype by TGF-β: “N1” versus “N2” TAN
Fridlender, Z. G., Sun, J., Kim, S., Kapoor, V., Cheng, G., Ling, L., Worthen, G. S., & Albelda, S. M. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.06.017 · Cited by 3,371
Regulatory T cells, tumour immunity and immunotherapy
Zou, W. (2006) · Nature Reviews Immunology · doi:10.1038/nri1806 · Cited by 2,085
Spranger, S., Dai, D., Horton, B., & Gajewski, T. F. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.04.003 · Cited by 1,441
Suppression of Antitumor Immunity by Stromal Cells Expressing Fibroblast Activation Protein–α
Kraman, M., Bambrough, P. J., Arnold, J. N., Roberts, E. W., Magiera, L., Jones, J. O., Gopinathan, A., Tuveson, D. A., & Fearon, D. T. (2010) · Science · doi:10.1126/science.1195300 · Cited by 1,134
Regulatory T cells in tumor immunity
Nishikawa, H., & Sakaguchi, S. (2010) · International Journal of Cancer · doi:10.1002/ijc.25429 · Cited by 944
Metadata
- Authors
- Yu, P., Lee, Y., Liu, W., Krausz, T., Chong, A., Schreiber, H., & Fu, Y.-X.
- Venue
- The Journal of Experimental Medicine
- Publisher
- Rockefeller University Press
- Published
- 2005-03-07
- Volume
- 201
- Issue
- 5
- Pages
- 779-791
- ISSN
- 0022-1007 (ISSN-L)
- 1540-9538
- OpenAlex
- W2132207502
- Cited by
- 432
- References
- 74
- FWCI
- 16.85
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.